Australian shares are set to open lower this morning after US stocks ended roughly flat overnight, as local traders await ...

Australian shares slipped off their all-time peak on Tuesday, dragged down by biotech major CSL’s steepest fall ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

By John Biju (Reuters) -Australian biotech firm CSL said on Tuesday it would spin off its influenza vaccine division and would cut up to 15% of its workforce as part of a strategic overhaul, sending ...

CSL also said it would restart a multi-year share buyback program from FY26, beginning with A$750 million. Chief Executive ...

SYDNEY] Australian biotech giant CSL said that it will spin off its Seqirus vaccine business into a separately listed company ...

Biotech giant CSL has reported a 17% increase in full-year statutory profit to US$3 billion ($4.6 billion) and announced ...

Australian biotech giant CSL Ltd. said it will spin off its Seqirus vaccine business into a separately listed company, as it reported full-year profit that was slightly higher than expected. CSL ...

Australia’s largest pharmaceutical company plans to spin off its Seqirus business into a separate ASX listing in the 2026 ...

Australian biotech giant CSL Ltd on Tuesday announced plans to demerge its influenza vaccine division, CSL Seqirus, and said it will lay off up to 15% of its workforce, after reporting a strong growth ...

One pharmacist tells ABC11, they're already seeing people getting sick with the flu, and the traditional flu season starts in ...

New research projects funded to combat avian influenza in swine focus on vaccine development, transmission risks, and biosecurity measures.